Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16993550 | 1.00 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL17000376 | 0.91 | FFAR1 (0.84) | FFAR1 | |
| SCHEMBL12191936 | 0.84 | FFAR1 (0.71) | FFAR1 | |
| SCHEMBL20103535 | 0.84 | FFAR1 (0.71) | FFAR1 | |
| SCHEMBL12191933 | 0.84 | FFAR1 (0.71) | FFAR1 | |
| SCHEMBL16993525 | 0.83 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL16993499 | 0.83 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL17000311 | 0.81 | FFAR1 (0.84) | FFAR1 | |
| SCHEMBL22365353 | 0.81 | FFAR1 (0.84) | FFAR1 | |
| SCHEMBL12193236 | 0.80 | FFAR1 (0.65) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | GPR119, GLP1R, GIPR | FFAR1 14/4885 |
| US-10059667-B2 | Antidiabetic compounds | GPR119, GLP1R, GIPR | FFAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.